Figure.S7 from Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma

Figure S7: Functional Validation of miR-126 and miR-145: A. Western blot of the miR-126 target S1PR2 in CD4+ T cells and Hut78 T cells transduced with empty vector or miR-126. B. Relative mRNA expression of S1PR2, BCL6, and PRDM1 in CD4+ T cells transduced with miR-126 compared to cells transduced with vector control. C. Flow cytometry histogram of CXCR5 expression in the Raji and DHL16 B-cell lines.D Flow cytometry assessment of the number of migrated CD4+ Jurkat cells expressing empty vector or miR-126, with S1PR2 inhibitor (JTE-013) E. Western blot of S1PR2 and RhoA-GTP in Jurkat cells transduced with empty vector or miR-126-vector treated with S1PR2 inhibitor (JTE-013) F. Cell viability in T cell lines after induction of miR-126 expression. G. Cell viability in Jurkat cells transduced with empty vector or miR-126 in combination with the drug JTE-013. H. Percentage of apoptotic cells in Jurkat cell cultures expressing empty vector or vector containing miR-126 I. Percentage of cells in phases of the cell cycle in Jurkat cell cultures expressing empty vector or vector containing miR-126. J. Expression of miR-145 in normal B cell subsets, CD3+ T cells and Stroma cells profiled using the qRT-PCR based ABI platform. K. Expression of miR-145 in PTCL subsets profiled using nCounter platform. L. miR-145 expression in Jurkat cells after ectopic expression of miR-145 or vector control. M. Cell viability in Jurkat cells transduced with vector control or miR-145.